ENT advisory panel
This article was originally published in The Gray Sheet
Executive Summary
FDA's Ear, Nose and Throat advisory panel will vote on a premarket approval application for Symphonix' Vibrant Soundbridge semi-implantable hearing device designed to treat moderate to severe sensorineural hearing loss, the most common form of hearing impairment, at a meeting July 20-21 in Gaithersburg, Maryland. The committee also will review an application for an implant intended to restore useful hearing to individuals with Neurofibromatosis Type II who have become deaf as a result of surgery to remove bilateral auditory nerve tumors